Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing

Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing

Abstract The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 patients who received nirmatrelvir-ritonavir (NR grou...

Full description

Saved in:
Bibliographic Details
Main Authors: Huaiya Xie, Yaqi Wang, Yan Xu, Luo Wang, Junping Fan, Siqi Pan, Chuan Shi, Xiaoyan Liu, Xiaoxing Gao, Xiaobei Guo, Siyuan Yu, Jia Liu, Dongming Zhang, Yanli Yang, Hong Zhang, Jinglan Wang, Aohua Wu, Xueqi Liu, Jihai Liu, Huadong Zhu, Xiang Zhou, Xinlun Tian, Mengzhao Wang
Format: Article
Language:English
Published: Nature Portfolio 2024-10-01
Series:Scientific Reports
Subjects:
Azvudine
Coronavirus disease 2019
Mortality
Nirmatrelvir-ritonavir
Seven-category ordinal scale
Online Access:https://doi.org/10.1038/s41598-024-74502-5
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 patients who received nirmatrelvir-ritonavir (NR group) or azvudine (FNC group) at Peking Union Medical College Hospital between 1 November 2022 and 27 February 2023. Patients in the FNC group (n = 304) were younger, exhibited less severe symptoms, started antiviral therapy later, received corticosteroids more frequently, and used tocilizumab less frequently than patients in the NR group (n = 412). Within 28 d of therapy, 40 (9.7%) and 20 (6.6%) deaths were in the NR and FNC groups, respectively. No differences were observed between drugs and mortality rates (odds ratio [OR] 0.78, 95% CI 0.40–1.5, P = 0.45), clinical improvement (OR 0.79, 95% CI 0.79–1.3, P = 0.38), and clinical progression (OR 1.0, 95% CI 0.58–1.8, P = 0.96). More patients in the NR group experienced platelet decline than those in the FNC group (17.6% vs. 8.9%, P = 0.034). This study indicated that the effectiveness and safety of azvudine were comparable to those of nirmatrelvir-ritonavir.
ISSN:2045-2322

Similar Items